Font Size




Menu Style

AVG Home

Future Events

The Symposium, Influenza 2018: Centenary of the 1918 Pandemic will be held at the Francis Crick Institute, London, UK from Sunday 24 to Tuesday 26 June 2018.

The programme for this 2-day Symposium will trace the development of current understanding of the nature of the viruses, the mechanisms of infection, virus replication and host (immune) responses, and the complex interplay between virus and host in pathogenesis and spread of disease. What are the prospects for developing a ‘universal’ vaccine and more effective antivirals?

A dedicated conference website will be opening soon.  The preliminary programme can be found here.

Picture or banner

Recent Event

The 5th isirv-AVG Conference entitled ‘Prevention and Treatment of RVIs: Antivirals, Traditional Therapies  and Host-Directed Interventions’ will take place at the Regal East Asia Hotel, Shanghai, China, 14-16 June 2017 

GISAID-ISIRV-WHO Workshop on ‘Genetic Analyses of Influenza Viruses’,  29th August 2016, Northwestern University, Chicago

GISAID in collaboration with Northwestern University and the International Society for Influenza and Other Respiratory Virus Diseases (isirv) organised a training workshop on Genetic Analyses of Influenza Viruses at Northwestern University on 29 August 2016 in Chicago, following the IX Options for the Control of Influenza Conference, 24-28 August.

The purpose of the training workshop was to enable laboratories to contribute to and benefit from the extensive genetic and related data on influenza viruses, in relation to understanding the epidemiology of influenza, the evolution of the viruses and the emergence and spread of novel genetic and antigenic variants. Participants were instructed in the use of GISAID’s new EpiFlu™ 2.0 database, its novel features and advanced analysis tools for the identification (and display on phylogenetic trees) and interpretation (using FluSurver) of mutations underlying the evolution and antigenic variation of human and animal influenza viruses. Enhanced capacity to analyse and understand the relationships among influenza viruses is aimed at stimulating increased interaction between institutions involved in human and animal influenza surveillance and research. The programme included a combination of brief lectures, demonstrations and hands-on training – seattached.


Group photo Bioinformatics Workshop Aug 2016

AVG Overview

The isirv Antiviral Group (isirv-AVG) was established as a special interest group of isirv at the time of merger in April 2011 of the former Neuraminidase Inhibitor Susceptibility Network (NISN) with isirv.

Its specific objectives are to promote understanding of the clinical use of antivirals against respiratory viruses, collate and provide up to date information on the emergence of antiviral resistance, and communicate expert commentary on preclinical and clinical development of potential novel/new antivirals in this area. Read More

AVG Meetings

Training Workshop on Genetic Analyses of Influenza Viruses, Hong Kong Polytechnic University, 21-22 November 2015

 GISAID-isirv Workshop-2

The 2-day training workshop on Genetic Analyses of Influenza Viruses, organised by isirv in conjunction with the GISAID Initiative, the WHO Global Influenza Surveillance and Response System and the Hong Kong Polytechnic University, was held at the Polytechnic University on 21-22 November 2015. The 33 trainees, from 24 countries, received instruction in the use of GISAID’s EpiFlu™ database and its new EpiFlu™ 2.0 platform, with its novel features and advanced analysis tools for the identification and interpretation of mutations underlying the evolution and antigenic variation of human and animal influenza viruses. Participants received financial support from the WHO, its Western Pacific regional office and isirv.

A summary report can be found here.

Texas banner 890

4th isirv Antiviral Group Conference, 2- 4 June 2015

The University of Texas at Austin, Texas, USA

The 4th AVG Conference held at the University of Texas on 2-4 June attracted a capacity audience of 200 registered participants. Against a backdrop of resistance to the licensed antivirals against influenza viruses and the lack of effective interventions against other respiratory viruses, the 3-day programme focused on the discovery and development of inhibitors of novel virus targets and key host cell factors. In relation to the development of monoclonal antibodies as therapeutics, the potential implications of antibody-dependent enhancement of disease were also addressed. The ten sessions covered the whole gamut of steps from structural and molecular biology to clinical studies, and included consideration of clinical trial endpoints and regulatory issues.

The inaugural ‘live’ twitter coverage was a very successful innovation. More than 160 tweets under the hashtag “#isirvAVG2015” were posted and the number of twitter “followers” of isirv-AVG doubled. The social media coverage not only showcased the speakers but also reached out to the wider scientific community. The "Meeting Report" can be foundheretwitter

NGS Meeting 2021 May 2015 - group photo 2

The Workshop on Next Generation Sequencing (NGS) of Viruses, organised by the isirv-AVG in conjunction with GISAID and the PREDEMICS Consortium, held at the Institut Pasteur, Paris on 20-21 May 2015 attracted 117 registered participants. The 2-day expert workshop covered various aspects of current sequencing technologies, data processing and analysis of data for a variety of RNA viruses, with a particular focus on quality and interpretation of results and the significance and use of NGS data for public and animal health.

A summary can be found here

Antiviral News


Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.

More than 99% of circulating viruses (n=14,330) tested during the 2015-2016 period were sensitive to all four neuraminidase inhibitors (oseltamivir, zanamivir, peramivir and laninamivir) with 0.8% showing reduced inhibition by at least one neuraminidase inhibitor. The most common neuraminidase amino acid substitution in A(H1N1)pdm09 virus is still H275Y. Four influenza B variants (B/Victoria-lineage) harbouring NA amino acid substitutions at H134N or G104E were found to confer resistance to NAIs. Based on these findings, neuraminidase inhibitors continue to be considered as an appropriate drug option for influenza treatment… read more

Monitoring influenza virus susceptibility to oseltamivir using a new rapid assay, iART.

The influenza Antiviral Resistance Test (iART), which utilises enzyme substrate for the measurement of neuraminidase activity for the rapid detection of resistance to oseltamivir, was tested on 149 clinical isolates and the results indicate that it is a valuable tool for resistance surveillance… read more 

Safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A challenge model: A Phase 2 randomized trial.

In a randomised, double-blind, placebo-controlled human challenge model, the treatment of subjects with a human monoclonal antibody, MHAA4549A, at different concentrations (400, 1200 or 3600 mg) between 24 to 36 hours post-infection with influenza A(H3N2) virus, was well-tolerated and significantly reduced virus shedding compared to placebo-treated arm… read more 

The hemagglutinin A stem antibody MEDI8852 prevents and controls disease and limits transmission of pandemic influenza viruses.

MEDI8852, a monoclonal antibody against hemagglutinin A stem antibody, ameliorates influenza A(H5N1) and A(H7N9) infection in both mice and ferrets when given either as a prophylactic or therapeutic dose. In particular, MEDI8852 was able to prevent ferrets from becoming infected via airborne transmission of influenza A(H1N1)pdm09 viruses…  read more 

Read More News


Visit us on:  facebook  twitter

Quick links:

Contact AVG:


Login to isirv members database

Click here for database login